SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-16-027494
Filing Date
2016-11-04
Accepted
2016-11-04 06:04:56
Documents
43
Period of Report
2016-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fprx-10q_20160930.htm 10-Q 1479227
2 EX-31.1 fprx-ex311_7.htm EX-31.1 8507
3 EX-31.2 fprx-ex312_10.htm EX-31.2 8505
4 EX-32.1 fprx-ex321_9.htm EX-32.1 5350
5 EX-32.2 fprx-ex322_6.htm EX-32.2 5243
6 GRAPHIC g201611031658555689849.jpg GRAPHIC 39878
  Complete submission text file 0001564590-16-027494.txt   4470014

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT fprx-20160930.xml EX-101.INS 969916
8 XBRL TAXONOMY EXTENSION SCHEMA fprx-20160930.xsd EX-101.SCH 21628
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fprx-20160930_cal.xml EX-101.CAL 41653
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fprx-20160930_def.xml EX-101.DEF 63033
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE fprx-20160930_lab.xml EX-101.LAB 208672
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fprx-20160930_pre.xml EX-101.PRE 153672
Mailing Address TWO CORPORATE DRIVE SOUTH SAN FRANCISCO CA 94080
Business Address TWO CORPORATE DRIVE SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS INC (Filer) CIK: 0001175505 (see all company filings)

IRS No.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36070 | Film No.: 161973537
SIC: 2834 Pharmaceutical Preparations